Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic corticosteroid plus ruxolitinib as first-line therapy in new-onset moderate to severe chronic graft-versus-host disease
KCT0010026Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in chronic graft-versus-host disease (cGVHD), sponsored by Novartis. Started Jan 2025; status: recruiting.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on KCT0010026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010026.